注射用重组人脑利钠肽联合托伐普坦在老年慢性心力衰竭患者中的应用

Application of Recombinant Human Brain Natriuretic Peptide for Injection Combined with Tovaptan in Elderly Patients with Chronic Heart Failure

目的:探讨注射用重组人脑利钠肽联合托伐普坦在老年慢性心力衰竭患者中的应用。方法:经深圳市盐田区人民医院医学伦理委员会批准后,选取2018年2月-2021年1月于本院接受治疗的68例老年慢性心力衰竭患者,依据随机数字表法将其分为观察组(34例)与对照组(34例)。两组入院后均给予利尿、抗感染、治疗原发病等常规治疗。观察组给予注射用重组人脑利钠肽、托伐普坦片联合治疗,对照组予以托伐普坦片治疗,用法用量同观察组,两组均持续治疗1周。比较两组治疗效果、治疗前后血清氨基末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)、左心室舒张末期内径(LVDD)水平及治疗过程中不良反应发生情况。结果:治疗1周后,观察组的总有效率高于对照组(P<0.05)。两组入院时血清NT-proBNP、LVEF、LVDD水平比较,差异无统计学意义(P>0.05);治疗1周后,两组血清NT-proBNP、LVDD水平均下降,且观察组低于对照组(P<0.05),LVEF水平均升高,且观察组高于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。结论:注射用重组人脑利钠肽联合托伐普坦用于老年慢性心力衰竭患者可以提高治疗效果,改善患者心功能,降低不良反应发生率。

Objective:To explore the application of Recombinant Human Brain Natriuretic Peptide for Injection combined with Tolvaptan in elderly patients with chronic heart failure.Method:With the approval of the medical ethics committee of Shenzhen Yantian District People’s Hospital,68 elderly patients with chronic heart failure treated in our hospital from February 2018 to January 2021 were selected,they were divided into the observation group (34 cases) and the control group (34 cases) by the random number table method.After admission,the patients in both groups were given routine treatment such as diuresis,anti infection and treatment of primary diseases.The patients in the observation group were treated with Recombinant Human Brain Natriuretic Peptide for Injection and Tolvaptan Tablets.The patients in the control group were treated with Tolvaptan Tablets.The usage and dosage were the same as those in the observation group.Both groups were treated for one week.The therapeutic effect,the levels of serum N-terminal pro brain natriuretic peptide (NT-proBNP),left ventricular ejection fraction (LVEF),left ventricular end diastolic diameter (LVDD) and the occurrence of adverse reactions were compared between the two groups before and after treatment.Result:After one week of treatment,the total effective rate of the observation group was higher than that of the control group (P<0.05).There were no significant differences in the levels of serum NT-proBNP,LVEF and LVDD between the two groups at the time of admission (P>0.05).After one week of treatment,the serum NT-proBNP and LVDD levels in the two groups decreased,and the levels in the observation group were lower than those in the control group (P<0.05),the LVEF levels were increased,and the level of LVEF in the observation group was higher than that in the control group (P<0.05).The incidence of adverse reactions in the observation group was much lower than that in the control group (P<0.05).Conclusion:Recombinant Human Brain Natriuretic Peptide for Injection combined with Tolvaptan in elderly patients with chronic heart failure can improve the therapeutic effect,improve cardiac function and reduce the incidence of adverse reactions.